HC Wainwright Analysts Cut Earnings Estimates for NovoCure

NovoCure Limited (NASDAQ:NVCR) – Research analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for NovoCure in a note issued to investors on Thursday, February 12th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will earn ($0.54) per share for the quarter, down from their previous estimate of ($0.50). HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.90) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($0.25) EPS, FY2029 earnings at $1.58 EPS and FY2030 earnings at $4.25 EPS.

A number of other analysts also recently commented on NVCR. JPMorgan Chase & Co. decreased their target price on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research note on Thursday, January 22nd. Wedbush reiterated a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research report on Thursday, January 15th. Finally, Evercore set a $20.00 price objective on shares of NovoCure in a research note on Monday, January 5th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $26.64.

NovoCure Trading Down 12.3%

Shares of NVCR opened at $10.99 on Monday. The firm’s 50-day moving average is $12.85 and its two-hundred day moving average is $12.61. The firm has a market capitalization of $1.23 billion, a P/E ratio of -6.83 and a beta of 0.73. The company has a current ratio of 1.55, a quick ratio of 1.50 and a debt-to-equity ratio of 0.57. NovoCure has a twelve month low of $9.82 and a twelve month high of $22.95.

Institutional Investors Weigh In On NovoCure

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC increased its position in NovoCure by 56.7% during the first quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock worth $512,000 after purchasing an additional 10,394 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of NovoCure by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after purchasing an additional 2,502 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of NovoCure by 5.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock worth $17,707,000 after purchasing an additional 52,180 shares during the period. Acadian Asset Management LLC acquired a new position in shares of NovoCure in the 1st quarter valued at about $87,000. Finally, KLP Kapitalforvaltning AS grew its holdings in shares of NovoCure by 6.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 1,400 shares during the period. 84.61% of the stock is owned by institutional investors and hedge funds.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.